Skip to main content

Craig-Hallum Reaffirms Their Buy Rating on MiMedx Group (MDXG)

Tipranks - Tipranks - Wed Oct 8, 2025

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on MiMedx Group. The company’s shares closed yesterday at $7.31.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Knickerbocker covers the Healthcare sector, focusing on stocks such as MiMedx Group, Harrow Health, and Celcuity. According to TipRanks, Knickerbocker has an average return of 28.1% and a 62.14% success rate on recommended stocks.

Currently, the analyst consensus on MiMedx Group is a Strong Buy with an average price target of $12.00, which is a 64.16% upside from current levels. In a report released on October 4, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $8.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on MiMedx Group’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $88.21 million and a net profit of $7.02 million. In comparison, last year the company earned a revenue of $84.71 million and had a net profit of $9.26 million

Read More on MDXG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).